Personalis Inc

F:04X

Volume growth: Personalis said clinical tests reached more than 7,800 in Q1, up 26% sequentially and 258% year over year, as adoption of NeXT Personal continued to accelerate.

Revenue mix shift: Q1 revenue was $15.5 million, but management said the mix is intentionally moving away from lower-margin legacy business toward higher-growth clinical and biopharma MRD revenue.

Guidance held: Full-year 2026 guidance was reaffirmed at $78 million to $80 million of revenue, with $20 million to $21 million of biopharma MRD revenue and $10 million to $11 million of clinical revenue.

Margins pressured: Gross margin fell to 1.8% in Q1, and management said margins should stay under pressure in the first half of the year before improving later as reimbursement ramps.

Reimbursement progress: Breast and lung cancer surveillance are now covered by Medicare, and the company also submitted neoadjuvant breast cancer and immunotherapy monitoring for review.

Cash and spending: Personalis ended the quarter with $233.2 million of cash and short-term investments, but expects about $100 million of cash usage in 2026 as it invests in growth, studies, and technology.